Onconetix Inc
ONCO1.520USD
-0.060-3.80%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
2.37MMarket Cap
0.00P/E TTM
More Details of Onconetix Inc Company
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Onconetix Inc Info
Ticker SymbolONCO
Company nameOnconetix Inc
IPO dateFeb 18, 2022
CEOFedasz (Karina M)
Number of employees5
Security typeOrdinary Share
Fiscal year-endFeb 18
Address201 E. Fifth Street
CityCINCINNATI
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code45202
Phone15136204101
Websitehttps://www.onconetix.com/
Ticker SymbolONCO
IPO dateFeb 18, 2022
CEOFedasz (Karina M)
Company Executives of Onconetix Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Simon Tarsh
Mr. Simon Tarsh
Independent Director
Independent Director
658.00
-5.60%
Mr. Andrew J. Oakley
Mr. Andrew J. Oakley
Lead Independent Director
Lead Independent Director
--
--
Dr. Thomas Meier, Ph.D.
Dr. Thomas Meier, Ph.D.
Independent Director
Independent Director
--
--
Mr. Timothy R. Ramdeen
Mr. Timothy R. Ramdeen
Independent Director
Independent Director
--
--
Ms. Karina M. Fedasz
Ms. Karina M. Fedasz
Interim Chief Executive Officer, Interim Chief Financial Officer
Interim Chief Executive Officer, Interim Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Simon Tarsh
Mr. Simon Tarsh
Independent Director
Independent Director
658.00
-5.60%
Mr. Andrew J. Oakley
Mr. Andrew J. Oakley
Lead Independent Director
Lead Independent Director
--
--
Dr. Thomas Meier, Ph.D.
Dr. Thomas Meier, Ph.D.
Independent Director
Independent Director
--
--
Mr. Timothy R. Ramdeen
Mr. Timothy R. Ramdeen
Independent Director
Independent Director
--
--
Ms. Karina M. Fedasz
Ms. Karina M. Fedasz
Interim Chief Executive Officer, Interim Chief Financial Officer
Interim Chief Executive Officer, Interim Chief Financial Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q1
FY2024
FY2023
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Switzerland
94.38K
92.87%
United Kingdom
7.25K
7.13%
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Altos Venture AG
17.51%
DRW Securities, LLC
3.96%
Citadel Advisors LLC
1.00%
Pacific Capital Wealth Advisors, Inc.
0.83%
Schiess (Ralph)
0.51%
Other
76.19%
Shareholders
Shareholders
Proportion
Altos Venture AG
17.51%
DRW Securities, LLC
3.96%
Citadel Advisors LLC
1.00%
Pacific Capital Wealth Advisors, Inc.
0.83%
Schiess (Ralph)
0.51%
Other
76.19%
Shareholder Types
Shareholders
Proportion
Corporation
18.38%
Investment Advisor
5.14%
Individual Investor
1.14%
Hedge Fund
1.10%
Research Firm
0.01%
Other
74.23%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
31
22.38K
5.65%
+17.05K
2025Q2
47
63.91K
38.67%
+44.58K
2025Q1
54
64.94K
25.23%
+43.00K
2024Q4
54
5.57M
44.93%
+3.81M
2024Q3
55
5.45M
45.59%
+5.19M
2024Q2
54
145.05K
20.85%
-52.13K
2024Q1
56
197.34K
30.36%
-46.00
2023Q4
55
198.08K
30.63%
+320.00
2023Q3
52
191.81K
46.53%
-6.38K
2023Q2
49
162.44K
39.14%
-37.83K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Altos Venture AG
273.23K
17.63%
+241.51K
+761.46%
Jul 14, 2025
Schiess (Ralph)
7.92K
0.51%
--
--
May 14, 2025
Bruhlmann (Christian)
7.19K
0.46%
--
--
May 14, 2025
Scablis AG
6.85K
0.44%
+6.85K
--
Sep 24, 2024
New Horizon Health Ltd
6.74K
0.43%
+6.74K
--
Sep 24, 2024
UBS Financial Services, Inc.
2.79K
0.18%
+2.73K
+4260.94%
Jun 30, 2025
Tower Research Capital LLC
330.00
0.02%
+243.00
+279.31%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 11, 2025
Merger
85→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Date
Type
Ratio
Jun 11, 2025
Merger
85→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
FAQs
Who are the top five shareholders of Onconetix Inc?
The top five shareholders of Onconetix Inc are:
Altos Venture AG holds 273.23K shares, accounting for 17.63% of the total shares.
Schiess (Ralph) holds 7.92K shares, accounting for 0.51% of the total shares.
Bruhlmann (Christian) holds 7.19K shares, accounting for 0.46% of the total shares.
Scablis AG holds 6.85K shares, accounting for 0.44% of the total shares.
New Horizon Health Ltd holds 6.74K shares, accounting for 0.43% of the total shares.
Altos Venture AG holds 273.23K shares, accounting for 17.63% of the total shares.
Schiess (Ralph) holds 7.92K shares, accounting for 0.51% of the total shares.
Bruhlmann (Christian) holds 7.19K shares, accounting for 0.46% of the total shares.
Scablis AG holds 6.85K shares, accounting for 0.44% of the total shares.
New Horizon Health Ltd holds 6.74K shares, accounting for 0.43% of the total shares.
What are the top three shareholder types of Onconetix Inc?
The top three shareholder types of Onconetix Inc are:
Altos Venture AG
DRW Securities, LLC
Citadel Advisors LLC
Altos Venture AG
DRW Securities, LLC
Citadel Advisors LLC
How many institutions hold shares of Onconetix Inc (ONCO)?
As of 2025Q3, 31 institutions hold shares of Onconetix Inc, with a combined market value of approximately 22.38K, accounting for 5.65% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -33.02%.
What is the biggest source of revenue for Onconetix Inc?
In FY2025Q1, the -- business generated the highest revenue for Onconetix Inc, amounting to -- and accounting for --% of total revenue.
